ArticleACR open rheumatology2025
Characteristics Associated With Detectable High-Sensitivity Cardiac Troponin in Patients With Rheumatoid Arthritis at Low-Intermediate Cardiac Risk.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarkers for Atherosclerotic Cardiovascular Events in Rheumatoid Arthritis: Towards Validation of a Biomarker-Enhanced Risk Model.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe objective of this study was to identify factors associated with detectable high-sensitivity cardiac troponin T (hs-cTnT), a marker of subclinical myocardial injury associated with cardiac events in rheumatoid arthritis (RA), among patients with RA at low to intermediate atherosclerotic cardiovascular disease (ASCVD) risk.
methodsWe performed a cross-sectional cohort study among patients with RA, excluding those with pre-existing cardiovascular disease or high estimated 10-year ASCVD risk (>20%). In univariable analysis, we compared demographics, RA clinical factors, markers of inflammation, and routine lipids among patients with and without detectable hs-cTnT. Multivariable logistic regression models were constructed to determine whether clinical factors and clinically available biomarkers were associated with detectable hs-cTnT, independent of ASCVD risk.
resultsWe studied 294 patients with RA, of whom 86 (29%) had a detectable hs-cTnT level. Older age; male sex; hypertension; higher levels of high-sensitivity C-reactive protein, interleukin-6, and lipoprotein-associated phospholipase A
conclusionDetectable hs-cTnT was prevalent among a cohort of patients with RA with low to intermediate ASCVD risk. Patients who were male or aged >60 had the highest rates of detectable hs-cTnT, suggesting a role for additional screening in these individuals regardless of their ASCVD risk.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.